Methods and kits for detecting ITA in a biological sample

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007920, C435S007940, C436S164000, C436S518000, C436S811000

Reexamination Certificate

active

07439026

ABSTRACT:
Methods for detecting invasive trophoblast antigen (ITA) in biological samples comprise screening the samples for ITA using antibodies that bind to the ITA. The methods are useful to detect pregnancy, trophoblastic diseases, and Down's syndrome in fetuses of pregnant women. Some methods include screening the samples with a plurality of capture antibodies that specifically bind ITA. Chemiluminescent immunoassays are disclosed. The methods may be practiced with the diagnostic kits of the invention.

REFERENCES:
patent: 4946958 (1990-08-01), Campbell et al.
patent: 5356817 (1994-10-01), Cole et al.
patent: 5506150 (1996-04-01), Canick et al.
patent: 5660990 (1997-08-01), Rao et al.
patent: 6127186 (2000-10-01), Pandian
patent: 6352862 (2002-03-01), Davis et al.
patent: 6500627 (2002-12-01), O'Connor et al.
patent: 6521416 (2003-02-01), Birken et al.
patent: 2002/0142305 (2002-10-01), Chin et al.
patent: 2002/0192646 (2002-12-01), Bellet et al.
patent: 2003/0157580 (2003-08-01), Hochstrasser et al.
patent: WO 00/61638 (2000-10-01), None
patent: 98/10282 (1998-03-01), None
patent: 99/41584 (1999-08-01), None
patent: 99/56132 (1999-11-01), None
patent: 00/42428 (2000-07-01), None
patent: 00/70094 (2000-11-01), None
Cole, Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites, Clinical Chemistry 43:12 2233-2243 (1997).
Birken et al., Immunochemical Measurement of Early Pregnancy Isoforms of hCG: Potential Applications to Fertility Research, Prenatal Diagnosis, and Cancer, Archives of Medical Research 32 (2001) 635-643, November.
Google search define: Hydatidiform mole.
ATCC, The Global Bioresource Center, Product Description, assecion No. PTA 1626, Aug. 21, 2007.
ATCC, The Global Bioresource Center, Product Description, assecion No. hb-12467, Aug. 21, 2007.
Biocompare, The Buyer's Guide for Life Scientists, Mouse Anti-hCG, intact Monoclonal Antibody, Unconjuaged, Clone 820.
AMS Biotechnology (europe) ltd, Monoclonal Antibody to hCG, intact, Purified—E45550M.
Biocompare, The Buyer's Guide for Life Scientists, Mouse Anti-hCG, beta Monoclonal Antibody, Unconjugated, Clone 827, Aug. 21, 2007.
Gentaur, Anti-H:, pp. 1-13, Aug. 21, 2007.
Bahado-Singh R et al., “A high-sensitivity alternative to ‘routine’ genetic amniocentesis: multiple urinary analytes, nuchal thickness, and age.” Am J Obstet Gynecol Jan. 1999;180(1 Pt 1): 169-73.
Cole LA et al., “Urinary screening tests for fetal Down syndrome: I. Fresh β-core fragment.” Prenat Diagn. Apr. 1999, 19(4): 340-50.
Bahado-Singh RO et al., “New triple screen test for Down syndrome: combined urine analytes and serum AFP.” J Matern Fetal Med. May-Jun. 1998;7(3):111-4.
Kellner LH et al., “Levels of urinary beta-core fragment, total oestriol, and the ratio of the two in second-trimester screening for Down syndrome.” Prenat Diagn. Dec. 1997;17(12):1135-41.
Cole La et al., “Combining beta-core fragment and total oestriol measurements to test for Down syndrome . . . ” Prenat Diagn. Dec. 1997;17(12):1125-33.
Cuckle HS et al., “Urinary multiple marker screening for Down's syndrome.” Prenat Diagn. Aug. 1995;15(8):745-51.
Bahado-Singh RO et al., “Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum triple screen for Down syndrome detection in high-risk pregnacies.” Am J Obstet Gynecol. Nov. 2000;183(5):1114-8.
Cole LA et al., “Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCG.” Premat Diagn. Apr. 1999; 19(4):351-9.
Cole LA et al., “Hyperglycosylated hCG, a potential alternative to hCG in Down syndrome screening.” Prenat Diagn. Sep. 1998; 18(9):926-33.
Hsu JJ et al., “Urine free beta-hCG and total estriol for Down syndrome screening during the second trimester in an Asian population.” Obstet Gynecol Jul. 1999;94(1):107-11.
Spencer K et al., “First-trimester urine free beta hCG, beta core, and total oestriol in pregnancies affected by Down's syndrome: implications for first-trimester screening with nuchal translucency and serum free beta hCG,” Prenat Diagn Jun. 1997;17(6):525-38.
Isozaki T et al., “Screening for Down syndrome pregnancy using β-core fragment: prospective study.” Prenat Diagn May 1997;17(5):407-13.
Spencer K et al., “Urine free beta hCG and beta core in pregnancies affected by Down's syndrome.” Prenat Diagn Jul. 1996;16(7):605-13.
Krichevsky A et al., “The development of a panel of monoclonal antibodies to human luteinizing hormone and its application to immunological mapping and two-site assays.” Endocrine 1994, 2, 551-520.
O'Conner JF et al., Differential Urinary Gonadotrophin Profiles in Early Pregnancy and Early Pregnancy Loss. Prenat Diagn 18: 1232-1240 (1998).
Unknown “Serum Hyperglycosylated hCG: a Potential Screening Test for Fetal Down Syndrome.” Prenat. Diagn. 19:488-490 (1999).
Cole LA et al., “Hyperglycosylated Human Chorionic Gonadotropin (Invasive Trophoblast Antigen) Immunoassay: A New Basis for Gestational Down Syndrome Screening.” Clinical Chemistry 45:12 2109-2119. (1999).
Abushoufa RA et al, “The development of a sialic acid specific lectin-immunoassay for the measurement of human chorionic gonadotrophin glycoforms in serum and its application in normal and Down's syndrome pregnancies.” Clinical Endocrinology (2000) 52, 499-508.
Birken S. et al., “Development and Characterization of Antibodies to a Nicked and Hyperglycosylated Form of hCG from a Choriocarcinoma Patient.” Endocrine, 10:(2) 137-144 Apr. 1999.
Krichevsky A. et al., “Development, Characterization, and Application of Monoclonal Antibodies to the Native and Synthetic βCOOH-Terminal Portion of Human Chorionic Gonadotropin (hCG) That Distiguishes between the Native and Desialylated Forms of hCG” Endocrinology Mar. 1994;134(3):1139-45.
Krichevsky A. et al. “Development and Characterization of a New, Highly Specific Antibody to the Human Chorionic Gonadotropin-β Fragment.” Endocrinology Mar. 1991;128(3):1255-64.
“Utility of Commonly Used Commercial Human Chorionic Gonadotropin Immunoassays in the Diagnosis and Management of Trophoblastic Diseases” by Cole et al.; Clinical Chemistry, Feb. 2001, vol. 47, No. 2, pp. 308-315.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods and kits for detecting ITA in a biological sample does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and kits for detecting ITA in a biological sample, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and kits for detecting ITA in a biological sample will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4011161

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.